Broadcom
AVGO
Taiwan Semiconductor
TSM
Tesla
TSLA
ASML Holding
ASML
Qualcomm
QCOM
US Stock MarketDetailed Quotes
VIGL Vigil Neuroscience
- 1.990
- -0.010-0.50%
Close Dec 13 16:00 ET
- 1.990
- 0.0000.00%
Post 20:01 ET
81.35MMarket Cap-0.96P/E (TTM)
2.095High1.930Low178.22KVolume2.040Open2.000Pre Close353.77KTurnover0.80%Turnover RatioLossP/E (Static)40.88MShares6.06052wk High0.92P/B44.16MFloat Cap1.93052wk Low--Dividend TTM22.19MShs Float18.270Historical High--Div YieldTTM8.25%Amplitude1.930Historical Low1.985Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Vigil Neuroscience Stock Forum
SEC· 21 mins ago
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily ...
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD).
The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerabi...
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
-July 30 9AM EDT
Vigil Neuroscience (Nasdaq: VIGL) announced three presentations on its small molecule TREM2 agonist VG-3927at the 2024 Alzheimer's Association International Conference (AAIC) in Philadelphia. The presentations include:
1. An oral presentation on the characterization of VG-3927 for clinical development in...
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
Vigil Neuroscience (Nasdaq: VIGL) has updated its clinical development strategy for iluzanebart in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)following a Type C Meeting with the FDA.
The company will preserve the IGNITE dataset for a final analysis at 12 months, foregoing an interim anal...
But it barely hit even 10 dollars. why is it so? hmm
Vigil Neuroscience, a clinical-stage biotechnology firm, recently disclosed a $40 million investment from Sanofi, a prominent player in the biopharmaceutical industry. This investment is set at an as-converted price of $7.44 per share of common stock, which stands notably higher than the previous day’s c...
No comment yet